IGF-1 LR3 vs HGH
The messenger and the hormone. Why one is a cell culture reagent and the other is an approved drug.
Reviewed by the amino101 editorial team. , first published .
IGF-1 LR3 and HGH sit on the same signaling axis one step apart, and the gap in evidence between them is as wide as any on this site. HGH is recombinant growth hormone, approved since 1985, with decades of human data; it works partly by telling the liver to produce IGF-1, which mediates most of its effects on muscle and bone. IGF-1 LR3 is a modified version of IGF-1 engineered to resist the binding proteins that normally hold it in reserve, giving it a 20 to 30 hour half-life and two to three times the potency of native IGF-1. It was built as a cell culture reagent and has no human trial data at all. Its reputation for muscle growth rests on rodent and cell studies plus anecdote. Both are prohibited by WADA, and both raise IGF-1 signaling, which carries the same theoretical cancer concern. The practical differences are route of effect, blood sugar, and how much is actually known. Educational comparison only.
| IGF-1 LR3 | HGH (Somatropin) | |
|---|---|---|
| Typical dosage | 20 to 50 mcg | 1 to 4 IU per day |
| Frequency | once daily | once daily, or split into two doses |
| Route | Subcutaneous, Intramuscular | Subcutaneous, Intramuscular |
| Half-life | 20 to 30 hours, because it is not captured by IGF binding proteins | 2 to 3 hours in plasma after subcutaneous injection; IGF-1 stays elevated for about 24 hours |
| Cycle | 4 to 6 weeks | 3 to 6 months minimum for body composition; medical replacement is ongoing |
| Research level | Preclinical only | Extensively studied |
| Human trials | None | Approved drug |
| Status | Research reagent, not FDA approved; banned in sport | FDA approved for growth hormone deficiency and several other indications; off-label and unlicensed use is widespread |
| Effects timeline | muscle fullness and pumps 1 to 2 weeks, recovery 2 to 4 weeks, any size change only over the full cycle with training and food | water retention and deeper sleep 1 to 2 weeks, skin and recovery 3 to 4 weeks, fat loss 8 to 12 weeks, lean mass 3 to 6 months |
Key differences
IGF-1 LR3 vs HGH (Somatropin) dosage
Dosage patterns reported in research and community protocols, by goal. Taken from each compound page. Not a prescription.
| Goal | Dosage | Frequency |
|---|---|---|
| First cycle | 20 mcg | once daily after training, with food |
| Standard | 40 mcg | once daily after training, with food |
| Upper end | 50 mcg | once daily, only if lower doses were tolerated |
| Training days only | 40 mcg | after each session, skipping rest days |
| Goal | Dosage | Frequency |
|---|---|---|
| Anti-aging, recovery, skin | 1 to 2 IU | once daily on waking or before bed |
| Body composition | 3 to 4 IU | split into two doses, morning and evening or post-training |
| Injury recovery support | 2 IU | once daily before bed |
| Medical adult replacement | roughly 0.6 to 1.5 IU (0.2 to 0.5 mg) | once daily, titrated to IGF-1 |
Convert any of these to syringe units in the dosage calculator.
Side effects compared
- ▲Hypoglycemia with shakiness, sweating, hunger, and brain fog
- ▲Headache
- ▲Water retention
- ▲Joint aches
- ▲Injection site pain or bruising
- ▲Fluid retention, swollen hands and feet
- ▲Joint pain and stiffness
- ▲Carpal tunnel symptoms, tingling and numb fingers
- ▲Elevated blood glucose and reduced insulin sensitivity
- ▲Headache
Which should you choose?
IGF-1 LR3 fits only experienced users whose goal is muscle specifically, who understand that there is no human data, and who will inject after training with a carbohydrate meal and keep fast carbohydrate on hand. Community protocols start at 20 mcg; most people find nothing above 50 mcg but more side effects. Short cycles of 4 to 6 weeks are the norm. It is not a fat loss compound and not a first peptide.
HGH fits the person who wants a documented effect on fat, water and recovery from an approved drug with decades of human data. It is the only one of the two that can be prescribed, monitored and dosed against a known IGF-1 target. Reported ranges run 1 to 2 IU daily for recovery and 3 to 6 IU for body composition, and it should be sourced from a pharmacy.
HGH is the one with a case for use; IGF-1 LR3 is the one with a case for caution. HGH is an approved drug with a known dose response, published side effects, and a direct fat loss effect. It raises IGF-1 the physiological way, through the liver, with binding proteins buffering the signal. LR3 bypasses all of that: it is unbound, long acting, and hits IGF-1 receptors everywhere for most of a day, with nothing that can be undone once injected. The hypoglycemia is real and the long term effects on tissue growth are unstudied in humans. For recovery, body composition or anti-aging, HGH at 1 to 2 IU is the better understood tool, and secretagogues are better understood still. LR3 belongs to a narrow group of experienced users chasing muscle specifically, running short 4 to 6 week cycles with food on hand. The two are sometimes stacked, which pushes blood glucose in opposite directions and is not something to do without bloodwork. Nothing here is a recommendation.
Stacking: Sometimes stacked for a stronger anabolic effect, injected at different times of day so the glucose effects do not overlap. HGH raises glucose; LR3 lowers it.
IGF-1 LR3 is a modified, long-acting version of insulin-like growth factor 1 that resists binding proteins and stays active for most of a day. People use it for muscle growth and recovery, and it carries a real risk of low blood sugar.
HGH is recombinant human growth hormone, a 191 amino acid protein identical to what the pituitary makes. It is an approved drug for growth hormone deficiency and is used off-label for fat loss, muscle preservation, recovery, and anti-aging.
IGF-1 LR3 vs HGH: frequently asked
Is IGF-1 LR3 stronger than HGH?
For direct anabolic signaling at the receptor, LR3 is more potent per microgram and acts for longer, because it is unbound and long acting. For overall effect on the body, including fat loss and the full range of GH actions, HGH does more, and it does it in a way that has been studied in humans. They are not interchangeable.
Can you take IGF-1 LR3 and HGH together?
Some people do, for a stronger anabolic effect. The combination pushes blood glucose in opposite directions, since HGH raises blood sugar and LR3 lowers it, so they are injected at different times of day. There is no trial data on the combination and it is not something to run without monitoring.
Does IGF-1 LR3 cause low blood sugar?
Yes, and it is the main acute risk. IGF-1 cross activates the insulin receptor at higher concentrations, and because LR3 is unbound and lasts 20 to 30 hours, the glucose drop can last for hours. Users report shakiness, sweating and brain fog when they inject without eating. Every community protocol pairs it with a carbohydrate meal.
Is IGF-1 LR3 legal?
It is sold as a research reagent and is not approved as a drug anywhere. Native IGF-1, mecasermin, is approved for a rare pediatric deficiency; LR3 is not that product. It is prohibited by WADA, as is HGH.
Which is better for fat loss, IGF-1 LR3 or HGH?
HGH. It directly stimulates lipolysis and reduces fat uptake into cells, which is where most of its effect in healthy adults shows up. LR3 is insulin-like and anabolic; it does not burn fat and can promote storage. For fat loss specifically, the GLP-1 drugs are in a different category from either.
Does injection site matter for IGF-1 LR3?
No, despite the folklore about injecting into a lagging muscle. The 20 to 30 hour half-life means it circulates systemically for most of a day, so where it goes in makes no difference to where it acts.
Related reading
Muscle growth and body composition
Inject the hormone itself, or ask your pituitary to make more? The trade-offs are not subtle.
Two IGF-1 family compounds sold for muscle. Neither has a human trial. What is the difference, and does the classic alternating protocol make sense?
Safety
Buying
Safety
Sources
- Effects of human growth hormone in men over 60 years old. New England Journal of Medicine, 1990
- The effects of growth hormone on body composition and physical performance in recreational athletes: a randomized trial. Annals of Internal Medicine, 2010
- Mecasermin (Increlex) prescribing information. US Food and Drug Administration, 2005